Momentum grows for earlier intervention, including pre-fibrotic disease
Other JAK inhibitors, combinations, and novel therapies offer more hope for patients
The procedure offers a potential cure, but comes with a risk of early morbidity and mortality
Genetics already informs prognosis, may help guide therapy development beyond JAK2 inhibition
Increased interest follows mutation discoveries, development of targeted therapies
